APA

Riedl M. A., Aygören-Pürsün E., Baker J., Farkas H., Anderson J., Bernstein J. A., Bouillet L., Busse P., Manning M., Magerl M., Gompels M., Huissoon A. P., Longhurst H., Lumry W., Ritchie B., Shapiro R., Soteres D., Banerji A., Cancian M., Johnston D. T., Craig T. J., Launay D., Li H. H., Liebhaber M., Nickel T., Offenberger J., Rae W., Schrijvers R., Triggiani M., Wedner H. J., Dobo S., Cornpropst M., Clemons D., Fang L., Collis P., Sheridan W. P. & Maurer M. (20190807). Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy.

Chicago

Riedl M A, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein J A, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon A P, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston D T, Craig T J, Launay D, Li H H, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner H J, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan W P and Maurer M. 20190807. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy.

Harvard

Riedl M. A., Aygören-Pürsün E., Baker J., Farkas H., Anderson J., Bernstein J. A., Bouillet L., Busse P., Manning M., Magerl M., Gompels M., Huissoon A. P., Longhurst H., Lumry W., Ritchie B., Shapiro R., Soteres D., Banerji A., Cancian M., Johnston D. T., Craig T. J., Launay D., Li H. H., Liebhaber M., Nickel T., Offenberger J., Rae W., Schrijvers R., Triggiani M., Wedner H. J., Dobo S., Cornpropst M., Clemons D., Fang L., Collis P., Sheridan W. P. and Maurer M. (20190807). Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy.

MLA

Riedl M A, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein J A, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon A P, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston D T, Craig T J, Launay D, Li H H, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner H J, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan W P and Maurer M. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy. 20190807.